papillary renal cell carcinoma (Cancer)
Information
- Disease name
- papillary renal cell carcinoma
- Disease ID
- DOID:4465
- Description
- "A renal cell carcinoma that is characterized by the development of multiple, bilateral papillary renal tumors." [url:http\://cancergenome.nih.gov/cancersselected/kidneypapillary, url:http\://www.omim.org/entry/605074]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03541902 | Active, not recruiting | Phase 2 | Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | May 15, 2018 | July 31, 2025 |
| NCT01767636 | Active, not recruiting | Phase 2 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | May 16, 2013 | November 16, 2024 |
| NCT03635892 | Active, not recruiting | Phase 2 | A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma | August 13, 2018 | August 2024 |
| NCT00126503 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | May 2005 | February 2012 |
| NCT00335556 | Completed | Phase 2 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | June 2006 | |
| NCT02489695 | Completed | Phase 2 | Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma | October 2015 | July 2019 |
| NCT06146777 | Not yet recruiting | Phase 3 | Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy | December 1, 2023 | December 1, 2030 |
| NCT06339138 | Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study | February 20, 2018 | January 31, 2027 | |
| NCT00898365 | Recruiting | Study of Kidney Tumors in Younger Patients | February 27, 2006 | ||
| NCT03866382 | Recruiting | Phase 2 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | May 13, 2019 | February 28, 2025 |
| NCT04071223 | Recruiting | Phase 2 | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study | July 29, 2020 | October 1, 2024 |
| NCT04413123 | Recruiting | Phase 2 | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | November 5, 2020 | December 20, 2025 |
| NCT04981509 | Recruiting | Phase 2 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | June 10, 2022 | December 31, 2024 |
| NCT05043090 | Recruiting | Phase 3 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC | October 28, 2021 | September 14, 2026 |
| NCT05620134 | Recruiting | Phase 1/Phase 2 | Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer | October 17, 2022 | February 20, 2026 |
| NCT04623502 | Recruiting | N/A | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy | September 30, 2019 | September 30, 2026 |
| NCT02837991 | Terminated | Phase 1 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma | June 2016 | November 16, 2018 |
| NCT00098618 | Terminated | Phase 2 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | October 2004 | |
| NCT04603365 | Withdrawn | Phase 2 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | October 18, 2021 | May 7, 2023 |
- Disase is a (Disease Ontology)
- DOID:4450
- Cross Reference ID (Disease Ontology)
- GARD:9572
- Cross Reference ID (Disease Ontology)
- MESH:C538614
- Cross Reference ID (Disease Ontology)
- MESH:D002292
- Cross Reference ID (Disease Ontology)
- MIM:605074
- Cross Reference ID (Disease Ontology)
- NCI:C27890
- Cross Reference ID (Disease Ontology)
- NCI:C6975
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:4797003
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1306837
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1336078
- Exact Synonym (Disease Ontology)
- Chromophil carcinoma of kidney
- Exact Synonym (Disease Ontology)
- papillary kidney carcinoma
- Exact Synonym (Disease Ontology)
- sporadic papillary renal cell carcinoma
- HPO alt_id (Human Phenotype Ontology)
- HP:0006776
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0006766
- OrphaNumber from OrphaNet (Orphanet)
- 319298